Data as of Mar 07
| -0.27 / -2.55%|
The 4 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 14.50, with a high estimate of 19.00 and a low estimate of 14.00. The median estimate represents a +40.78% increase from the last price of 10.30.
The current consensus among 5 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.